back to endpoints news

Endpoints News

Endpoints News

Essential biotech news and analysis
Independent journalism, every business day in your inbox

Full article text inside the email. Uncluttered design. Sharp writing. And it's absolutely free — or you can pay to get Endpoints without the email advertising. Corporate subscriptions are one simple price, regardless of size. Never miss an important drug development story again.

Subscribe

Daily Subscriptions

Endpoints News is an independent journalism company. Readers fund our growth with Insider subscriptions, ensuring our long-term viability. Advertising from trusted partners screened by Endpoints guarantees access for all to quality journalism. Read our privacy policy or see this post on our business model. No refunds. You can cancel your subscription anytime. Enterprise plans are governed by these terms and conditions .


Compare Plans

Basic

Insider

Enterprise

FREE

$200/year

$1,000/year

Join Join
Feature Edition newsletter
check-thin check-thin check-thin
Full-text articles inside email
check-thin check-thin check-thin
Early Edition newsletter
check-thin check-thin check-thin
Friday Insider column
  check-thin company-wide
Disable email ads
  check-thin check-thin
up to 3 employees
Customer support
72 hrs 24 hrs First-in-line
Fair use cut-and-paste
check-thin check-thin check-thin
Guilt-free cut-and-paste
  check-thin company-wide
Print-to-PDF
  check-thin check-thin
Rebroadcast rights
    company-wide
Reprint rights
    company-wide
Post to Slack or private API
    check-thin
Support independent journalism
check check
 

For Professionals

Endpoints Insider

Directly support our mission to deliver quality biotech journalism to the widest audience possible
$200/year

Exclusive Benefits


Disable Email Marketing

Prefer to read us without getting the sponsored emails? Insiders can opt-out.

News Articles in PDF

Clean and optimized for print, download any article directly to your computer as a PDF.

Exclusive Insider Column

John Carroll’s weekly opinion column runs most Fridays. Exclusive to paid subscribers.

Ad-free Experience

We only run ads from trusted partners. Nevertheless, paid subscribers can disable them.

Priority Email Support

Trouble with email delivery? Our techs will help figure out what's wrong.

Early Adopt Our Model

Play a crucial role as an early adopter of for-profit, independent biznews reporting. Directly fuel our growth.


... and more to come.

Already a subscriber? Need help? Click here.


For Companies

Enterprise

$1,000/year per company (no matter what size)

For companies of all sizes and purposes. Share full-text Endpoints News content however you like. White-label it for private clients, broadcast to an intranet, post an article on your company website, or reprint for tradeshow marketing, and more.

Enterprise Plans Include


Full Reprint Rights

Reproduce our content in full, print and online, inside your company or for private clients.

Newsletter forwarding

Forward our email newsletters to internal broadcast channels or listservs.

Private Newsfeed

We can provide a private connection to our server so your techs can display Endpoints articles on your intranet.

VIP Email Support

Our techs will help your techs if your company has trouble with our email delivery. It'll be our top priority.

Use Content for IRL Marketing

Tradeshows, sales presentations, fundraising meetings. Need to print lots of our content? The Enterprise Plan gives you that right.

Terms and Conditions

Reprint, broadcast, and related rights are granted to every full-time employee at an Enterprise Plan licensed company. Ad-free experience is limited to 3 employees. Any extra "paywall" content will be made available to all employees. You may republish our content privately, for your own company or for clients. You can cancel the subscription at anytime, but there are no refunds. Full terms.


One simple $1,000/year license
Every company size, mega to tiny.

More questions? Click here for the Endpoints News team.


Thank you for staying with us. It's great to have you on board!
Aww, shucks. Perhaps you can tell us what we could do to make you interested in subscribing?
← Go back